Mizunuma H, Honjo H, Aso T, Urabe M, Ohta H, Kobayashi S, Sagara Y, Sanada M, Tanaka K, Dobashi K, Hayashi K, Ohama K
Japan Society of Obstetrics and Gynecology, Faculty of Medicine, Gunma University, Gunma, Japan.
Climacteric. 2001 Dec;4(4):293-8.
The relationship between the risk of endometrial cancer and the use of noncontraceptive estrogens by Japanese postmenopausal women was investigated in a hospital-based case-control study of 1025 women with endometrial cancer and 1267 with other conditions. The overall odds ratio (OR) for estrogen use with or without progestins, compared with never use of any type of estrogens, was 0.917 (95% confidence interval (CI) 0.622-1.353), suggesting that hormone replacement therapy is not a causative agent for endometrial cancer in Japanese women, and that a recent increase in the incidence of endometrial cancer in Japanese women may be related to changes in their life-style. However, although not statistically significant, women who used estrogen without progestin for 12 or more months had an OR of 2.552 (CI 0.231-28.192), while those who used estrogen with progestin for 12 or more months had an OR of 0.425 (CI 0.086-2.113). These results indicate that the addition of a progestin should be considered for reducing the risk of endometrial cancer in Japanese women.
在一项基于医院的病例对照研究中,对1025名子宫内膜癌女性患者和1267名患有其他疾病的女性进行了调查,以研究日本绝经后女性子宫内膜癌风险与使用非避孕雌激素之间的关系。与从未使用过任何类型雌激素的女性相比,使用含或不含孕激素的雌激素的总体优势比(OR)为0.917(95%置信区间(CI)0.622 - 1.353),这表明激素替代疗法不是日本女性子宫内膜癌的致病因素,并且日本女性近期子宫内膜癌发病率的上升可能与她们生活方式的改变有关。然而,尽管无统计学意义,但使用不含孕激素的雌激素达12个月或更长时间的女性优势比为2.552(CI 0.231 - 28.192),而使用含孕激素的雌激素达12个月或更长时间的女性优势比为0.425(CI 0.086 - 2.113)。这些结果表明,为降低日本女性子宫内膜癌的风险,应考虑添加孕激素。